Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application - Wikidata - wikimedia - TriplyDB

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

http://www.wikidata.org/entity/Q26858779

about

Vaccines for pancreatic cancer Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response Immunotherapy in the treatment of non-small cell lung cancer PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab Intracellular CTLA4 and regulatory T cells in patients with laryngeal squamous cell carcinoma.Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.Recent new drug approvals, part 2: drugs undergoing active clinical studies in children Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.New developments in castrate-resistant prostate cancer.Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells.Anti-CTLA-4 therapy for malignant mesothelioma.Comparative antitumor effect of preventive versus therapeutic vaccines employing B16 melanoma cells genetically modified to express GM-CSF and B7.2 in a murine model IL-10: Expanding the Immune Oncology Horizon.New treatment approaches in melanoma: current research and clinical prospects.Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities.Melanoma: the role of surgery in the era of new therapies.Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".Trial watch: Immune checkpoint blockers for cancer therapy.Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines.Current challenges for cancer vaccine adjuvant development.PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours.[Targeted therapies for melanoma].

P2860

Q26825850-E3FAB8BC-B8EC-43CE-8E33-F133FFA9960E Q26863081-70006C2D-94D6-4AA4-BD06-6CD8428A5F86 Q27000382-FAFA167B-8E67-4732-9C8C-31049EFFFF6A Q28073874-6393A35B-6225-4CBF-A05A-BE270AF307EE Q34646640-CF3683AA-1022-4419-B6EF-E1C6B2F9BD2A Q36213487-23A3DFB0-6F4A-47CE-9933-6840B9A7154F Q36764984-3C41B880-91ED-4825-96AA-699C0BD4703D Q36765800-D864532F-01E4-4ED9-8BB1-9AF8D1C6DF0A Q37701881-CA896A0E-8A80-4DFF-835E-DC63B8089C81 Q38016532-89873DDA-97E2-424F-BB8C-A9BA11CF27C4 Q38068205-69A330CE-FD22-4F0B-B6D5-AEBC1F9D4029 Q39103523-C854563B-DBE4-45E9-B3BD-176BA7F30289 Q39148274-8129D5B4-620E-4D9D-AC1C-A3B5FDA18302 Q39234383-4738D518-5719-4C61-80E6-B3EEB02E025A Q40217856-D236F117-BFC9-484D-A4C2-561F5944254C Q41869110-D16F9058-E2AF-4F25-AAC4-CF12F2683B8C Q42145973-830CEE9D-433F-4960-9B00-F865C51B3456 Q42744580-5D3DD5A5-63AB-47F7-B895-EAA1BCEF345E Q43215055-F62FBE3B-8942-4EF2-BB6D-B00575B9678F Q47393365-816F1D72-C114-4D2C-8087-F61BBD5B29DF Q47720344-8F46FFA6-3EEA-4F88-8750-7A091CCCDAF3 Q48160317-2A2A021F-E09D-437D-BEAA-8791BB6F3C69 Q52723008-CB545E04-EF15-4FFA-A94F-E47DDF49F8F4 Q55073531-B7F98464-94EA-4D12-9CC9-D6477DA59676

P2860

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

http://www.wikidata.org/entity/Q26858779

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

@ast

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

@en

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

@nl

type

label

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

@ast

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

@en

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

@nl

prefLabel

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

@ast

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

@en

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

@nl

P1433

Q26858779-CE4934DC-43B3-47FB-B3E6-7D5276860FD9

P1476

Q26858779-BDAB661F-D5C0-4AF8-BDCF-91E9DC4C3DD8

P2093

Q26858779-B9A635B3-BC7B-4646-A3F1-6A52BA523AAD

P275

Q26858779-E7273F13-3CED-4E04-B579-680D6399A99D

P2860

Q26858779-17F31BFB-F5B6-47CA-8DEF-FD9E1CC6B069

Q26858779-1D0BD9C5-C0AA-43DA-AA57-D6A7BA1CF3C6

Q26858779-1DF507BF-3BB3-42EC-81CD-9C2E03C54911

Q26858779-27365681-9EA5-41DA-93DC-DE5680967CE4

Q26858779-2DC84D53-E38C-4756-A27D-E669E7169381

Q26858779-32C910A6-0771-49C8-BD3A-0824BA3F66FB

Q26858779-71536D47-9E25-4A3A-93E5-942A9E18F010

Q26858779-81C28B85-EA01-4F81-8AF0-5B2A96ECBF8D

Q26858779-82D87019-3F11-4DA8-A11B-0D31A649E792

Q26858779-853E822B-DEC9-4EC3-91EC-03C27785A807

P2888

Q26858779-541A4D2A-7B44-4338-ACA2-6E73AC59DF05

P304

Q26858779-D64DD71E-565B-43EC-8D7D-37B160A11100

P31

Q26858779-5E5F1A27-135A-4533-9006-E57EF93515F2

Q26858779-72F22BC0-63BC-4CD1-8747-51BABF20B520

Q26858779-97a2873d-71e7-4f6a-8855-40be82b86ec0

P356

Q26858779-3F147ADE-0820-4D71-8251-A23E9B6E4BB3

P407

Q26858779-6751A442-48CC-44F4-9ED0-5D9A04BA4D30

P478

Q26858779-4F3EDC5D-CC45-4813-85F2-5D430571BFFF

P50

Q26858779-57A527DD-9ED1-4814-A45B-7594F5017A00

Q26858779-DF0F5314-6C78-472A-95CC-210E545BDA8D

P577

Q26858779-2215DBA1-3D2E-468C-BD1C-605CBEEB5A5D

P5875

Q26858779-AE79D44D-123C-4DA3-8B57-3311BF1CB721

P6179

Q26858779-1FED1593-DD4A-4981-B1F6-9B940CA6795D

P698

Q26858779-1186ADD7-F4E0-4738-947E-4A6BEEF83F23

P921

Q26858779-050FFB11-0DDA-4BA9-AB83-15713CCF3C4A

Q26858779-406A36C5-93EF-4AF0-AF70-F76FEACC40F8

Q26858779-88589672-9577-47FC-BBAB-8333D8033DEB

Q26858779-8D04B3AD-B965-424E-85DC-551BA5C0631E

Q26858779-9F0A8B09-9232-487D-B84F-00715DB7BD60

Q26858779-DBDF91CC-554B-4C5E-85DD-0F098B0A624F

Q26858779-ECF1ABBF-96F1-4144-8499-F60405B7F8BA

P932

Q26858779-6FFEE16D-70F4-4350-83B1-274AABC28BAF

P356

1479-5876-9-196

P1433

Journal of Translational Medicine

P1476

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

@en

P2093

Francesco M Marincola

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma.

Melanoma: a model for testing new agents in combination therapies.

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.

P2888

1479-5876-9-196

P304

196

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-9-196

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Antonio Ascierto

P577

2011-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51793608

http://www.w3.org/2001/XMLSchema#string

P6179

1002642894

http://www.w3.org/2001/XMLSchema#string

P698

22077981

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

monoclonal antibody

membrane proteins

biomedical investigative technique

P932

3262765

http://www.w3.org/2001/XMLSchema#string